Evidence map›Paper›PMID 26506968›Full record

ArticleAnnals of Saudi medicine

High-volume hemofiltration plus hemoperfusion for hyperlipidemic severe acute pancreatitis: a controlled pilot study.

Shiren Sun, Lijie He, Ming Bai, Hongbao Liu, Yangping Li, Li Li, Yan Yu, Meilan Shou, Rui Jing, Liyuan Zhao and 2 more

Registry-linked trialOpen access · diamondAbstract readControlled Clinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of Saudi medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05941624 (Comparison Between HA330 Hemoperfusion Filter Hemodialysis and Conventional High-Flux Filter Hemodialysis in Reducing Inflammatory Mediators in Renal Dysfunction Due to Sepsis), which is not on this map. Cited by 22 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 3 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05941624 nacompletednot on this map

Comparison Between HA330 Hemoperfusion Filter Hemodialysis and Conventional High-Flux Filter Hemodialysis in Reducing Inflammatory Mediators in Renal Dysfunction Due to Sepsis

TypeinterventionalSponsorIndonesia UniversityRan2023 to 2024Enrolled33ConditionsRenal Dysfunction, Sepsis, HemodialysisArmsHa-330 Hemoperfusion Filter Hemodialysis, Conventional Hemodialysis
3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Observational
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Shiren SunDr. Shiren Sun, Department of Nephrology,, Xijing Hospital,, The Fourth Military Medical University,, No. 127 Changle West Road,, Xi'an, Shhanxi 710032, China, T: +8602984775193, F: +8602984773494, shirensunfmmu@163.com.
Lijie He
Ming Bai
Hongbao Liu
Yangping Li
Li Li
Yan Yu
Meilan Shou
Rui Jing
Liyuan Zhao
Chen Huang
Hanmin Wang
Air Force Medical University · CNXijing Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesThe evidence for high-volume hemofiltration plus hemoperfusion (HVHF&HP) for hyperlipidemic severe acute pancreatitis (HL-SAP) is anecdotal. The purpose of our study was to evaluate the efficacy of HVHF&HP for HL-SAP in a prospective controlled study. DESIGN AND

settingProspective controlled pilot study between May 2010 and May 2013 in a hospital intensive care unit. PATIENTS AND

methodsHL-SAP patients chose conventional treatment alone (the control group) or conventional treatment combined with the experimental protocol (the HVHF&HP group) and were prospectively followed in our hospital. APACHE II score, SOFA score, ICU and hospital stay duration, and serum biomarkers were considered endpoints.

resultsTen HL-SAP patients accepted conventional treatment alone (the control group) and 10 patients underwent HVHF&HP combined with conventional treatment (the HVHF&HP group). The APACHE II score, SOFA score, systolic blood pressure, diastolic blood pressure, heart rate, serum amylase, and serum creatinine were significantly reduced after the HVHF&HP treatment. The changes in these variables were significantly different between the HVHF&HP and control group at 48 hours after the initiation of treatment. Patients in the HVHF&HP group had a significantly shorter ICU stay (P=.015). The reduction in serum triglyceride and cholesterol in the HVHF&HP group after 2, 6, 12, 24, and 48 hours was greater than the control group. All of the tested serum cytokines were significantly decreased after HVHF&HP treatment (P < .05). However, in patients who underwent conventional treatment alone, there was no significant change in the serum cytokines.

conclusionThis study suggests that the addition of HVHF&HP to conventional treatment for HL-SAP patients may be superior to conventional treatment alone for the improvement of serum biomarkers and clinical outcomes.

Indexed as

AdultAmylasesAPACHEBiomarkersBlood PressureCholesterolCombined Modality TherapyCreatinineCytokinesFemaleHeart RateHemofiltrationHemoperfusionHumansHyperlipidemiasMaleAmylasesBiomarkersCholesterolCreatinineCytokinesTriglycerides

Identifiers

PMID26506968
PMCPMC6074380
OpenAlexW2474547786

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.